Chronic Pain News and Research

RSS

St. Jude Medical announces implantation of the first patient in China with its Eon rechargeable neurostimulator

St. Jude Medical, Inc. announced today that a 62-year-old man from Shenzhen, Guangdong province has become the first patient in China to be implanted with the Eon™ neurostimulator, a rechargeable device used to help manage chronic pain. Despite prior back surgeries, the patient suffered from chronic back pain for more than a decade.

18 Nov 2009

Cancer pain drug market to be $3.7 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the continued dominance of opioids that include immediate-release morphine and novel fast acting opioid reformulations, the cancer pain drug market will increase from $2.3 billion in 2008 to $3.7 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

17 Nov 2009

FDA approves Par Pharmaceutical's new painkiller drug

Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for the 100mg and 200mg strengths of tramadol ER.

17 Nov 2009

Chronic pain patients with depression three times more likely to receive opioid medications

Chronic pain patients with a history of depression are three times more likely to receive long-term prescriptions for opioid medications like Vicodin compared to pain patients who do not suffer from depression, according to new research.

16 Nov 2009

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

13 Nov 2009

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Abbott announced today a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain.

13 Nov 2009

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain.

13 Nov 2009

Millennium Laboratories announces new clinical quantitative assay and drug screening tests for healthcare

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, announced today the company’s development and validation of a clinical quantitative assay for the new drug tapentadol (Nucynta™) by liquid chromatography/tandem mass spectrometry (LC-MS/MS).

12 Nov 2009

U.S. DOD grant to study vigabatrin in combination with opiates to manage pain

Catalyst Pharmaceutical Partners, Inc. today reported that a team of neuroscientists at The Feinstein Institute for Medical Research at North Shore-Long Island Jewish Health System (LIJ) has received a $1.2 million grant from the U.S. Department of Defense (DOD) to conduct an animal study of the use of vigabatrin in combination with opiates to effectively manage pain while reducing the potential for opiate addiction.

10 Nov 2009

National Pain Summit calls for better pain care in America

Pain medicine physicians from the American Academy of Pain Medicine (AAPM) continued to advance the call for better pain care as they joined with physician leaders from across the country in a closed-door National Pain Summit that took place adjacent to an AMA meeting last week in Houston, Texas.

10 Nov 2009

Cannabinoid medicine: Challenges for health care providers and its potential benefits for patients

Groundbreaking articles in current issues of Journal of Opioid Management, for the first time explore, in depth, the emergence of cannabinoid medicine, its challenges for health care providers and its potential benefits for patients.

10 Nov 2009

Military personnel with back pain unlikely to return to duty after treatment

Military personnel evacuated out of Iraq and Afghanistan because of back pain are unlikely to return to the line of duty regardless of the treatment they receive, according to research led by a Johns Hopkins pain management specialist.

9 Nov 2009

FDA grants marketing approval for Wright Medical Group's CONSERVE Plus Total Hip Resurfacing System

Wright Medical Group, Inc., a global orthopaedic medical device company, announced today that the United States Food and Drug Administration (FDA) has given approval to the Company to market its original CONSERVE® Plus Total Hip Resurfacing System. Now available in the United States, this innovative total surface arthroplasty system provides surgeons and their patients a bone-conserving alternative to traditional total hip replacement.

9 Nov 2009

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

Progenics Pharmaceuticals, Inc. today announced its results of operations for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Raptor Pharmaceutical Corp., today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco.

5 Nov 2009

Spinal Modulation completes its $27.4 million Series C financing

Spinal Modulation, Inc. announced today the completion of its $27.4 million Series C financing. Johnson & Johnson Development Corporation (JJDC) joined existing major investors including DeNovo Ventures, ePlanet/DFJ, Kleiner Perkins Caufield & Byers, and MedVenture Associates in this financing. DFJ/InCube Ventures and Raffles Venture Partners are additional new investors.

4 Nov 2009

Researchers to find better ways to manage chronic pain by treating neuroinflammation

Thanks to a two year, $974,024 NIH-funded ARRA (American Recovery and Reinvestment Act) grant, Saint Louis University and Southern Illinois University Edwardsville researchers are working to find better ways to manage chronic pain by treating neuroinflammation.

4 Nov 2009

Obese lung cancer patients with diabeties more likely to develop chest wall pain after receiving stereotactic body radiation therapy

Obesity, not the amount of radiation given, is the greatest factor in whether early-stage lung cancer patients develop chest wall pain after receiving stereotactic body radiation therapy to the chest wall, with obese patients being more than twice as likely to develop chronic pain compared to those who have less body weight, according to a first-of-its-kind study presented Tuesday, November 3, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

4 Nov 2009

NIH awards $2 million grant for sickle cell disease research

Researchers at the University of Illinois at Chicago will use a $2 million federal grant to investigate why patients with sickle cell disease experience chronic pain -- and to develop drugs to treat it.

2 Nov 2009

New hope for chronic pain sufferers

In an Anglo-Italian study, thirty healthy subjects were invited to look at either their own hand, the experimenter's hand, or an object, while their hand was subjected to laser-induced pain.

30 Oct 2009

Chronic Pain News and Research

St. Jude Medical announces implantation of the first patient in China with its Eon rechargeable neurostimulator

Cancer pain drug market to be $3.7 billion in 2018

FDA approves Par Pharmaceutical's new painkiller drug

Chronic pain patients with depression three times more likely to receive opioid medications

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

Millennium Laboratories announces new clinical quantitative assay and drug screening tests for healthcare

U.S. DOD grant to study vigabatrin in combination with opiates to manage pain

National Pain Summit calls for better pain care in America

Cannabinoid medicine: Challenges for health care providers and its potential benefits for patients

Military personnel with back pain unlikely to return to duty after treatment

FDA grants marketing approval for Wright Medical Group's CONSERVE Plus Total Hip Resurfacing System

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Spinal Modulation completes its $27.4 million Series C financing

Researchers to find better ways to manage chronic pain by treating neuroinflammation

Obese lung cancer patients with diabeties more likely to develop chest wall pain after receiving stereotactic body radiation therapy

NIH awards $2 million grant for sickle cell disease research

New hope for chronic pain sufferers

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News